We have also demonstrated recently that BM-Ads might favor the homing of CCR3 expressing prostate cancer (PCa) cells through their ability to secrete the CCL7 chemokine (Guerard et al. 2021 Int J Mol Sci). Interesting the CCR3/CCL7 axis is also involved in local PCa invasion in a process dependent of the secretion from mature adipocytes of the periprostatic adipose tissue (Laurent et al. 2016 Nat Commun). The implication of CCR3 in both local and distant invasion of PCa highlights the interest of use of CCR3 inhibitors in PCa.
Our current project aims to decipher the role and nature of the metabolic cross talk between PCa cells and BM-Ads in bone metastasis outgrowth in order to propose innovative drug targets for the treatment of PCa bone metastases. We recently reviewed how tumor cells affect the in vitro and in vivo phenotype of BMAds and the signals emanating from BMAds that are susceptible to modulate tumor behavior with a specific emphasis on their metabolic crosstalk with cancer cells (Hernandez et al. 2022 Cancer Metastasis Rev). This project has been funded in 2020 by the French National Cancer Institute and is supported by the Ligue Nationale contre le Cancer (labeled team 2020-2025).